InvestorsHub Logo

Couch

11/28/14 1:39 PM

#136769 RE: dr_lowenstein #136764

better than what? the comparator did not have ADT, so that statement is misinformation


Misinformation?? Hysterical to say the least....what misinformation??? Just bc the company did not release the name of the company does not mean it is misinformation. But hey I'll tell you who the competitor was.....as I did from day one here. It's Pfizer with its weak ass Embeda.

As I've stated.... A BETTER EMBEDA is coming!!!

The study results demonstrated statistically significant (p <.0001) lower measures of drug liking, drug high and good drug effects for Elite’s manipulated (crushed) ELI-200 when compared to the manipulated (crushed) drug listed comparator product and found 91.9% of the subjects experienced increased drug liking with the comparator product compared to ELI-200 in non-dependent recreational drug users when administered intranasally. The study also found 80.6% of the subjects experienced a decrease in drug liking with the intranasal crushed ELI-200 in comparison to the administration of oral intact ELI-200.